Celia Oreja-Guevara (Vice Chair of Neurology and Head of Multiple Sclerosis Center, University Hospital San Carlos, and Professor of Neurology, University Complutense, Madrid, Spain) discusses the background and findings of her presentation entitled: Patient involvement in treatment decision-making: a sub-analysis of the ‘MS in the 21st Century international unmet needs survey’ comparing patient and healthcare professional perspectives.
1. What is the ‘MS in the 21st Century’ initiative? (0:12)
2. What was the objective of the sub analysis that you’re presenting here at EAN? How were the data collected? (1:06)
3. What did the data reveal about approaches to treatment discussions and the factors that influence treatment decisions? (2:30)
4. What impact do you hope these findings will have on treatment decision-making in the future? (4:03)
Speaker disclosure: Celia Oreja-Guevara has nothing to disclose in relation to this video interview.
‘MS in the 21st Century’ is a Merck KGaA, Darmstadt, Germany initiative involving healthcare professionals and patient advocates
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
Share this Video
Related Videos In Multiple Sclerosis
Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study
Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]
Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis
The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the aim, designs and outcomes of these studies as well as the subpopulation analyses […]
Enrique Alvarez, AAN 2023: Ublituximab for participants with relapsing multiple sclerosis
The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the unmet needs of this population and the mechanism of action of ublituximab. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!